Answers are grounded in this paper and cite their sources.
Review demonstrates inflammatory and immune mechanisms driving muscle damage in Duchenne muscular dystrophy, highlighting therapeutic strategies to support dystrophin replacement.
Immunological and inflammatory processes downstream of dystrophin deficiency as well as metabolic abnormalities, defective autophagy, and loss of regenerative capacity all contribute to muscle pathology in Duchenne muscular dystrophy (DMD). These downstream cascades offer potential avenues for pharmacological intervention. Modulating the inflammatory response and inducing immunological tolerance to de novo dystrophin expression will be critical to the success of dystrophin-replacement therapies. This Review focuses on the role of the inflammatory response in DMD pathogenesis and opportunities for clinical intervention.
No takes yet. Share an insight, caveat, or question.
Rosenberg et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: